Utama › Penyakit Autoimun › Illinois › Chicago
Kajian klinikal Penyakit Autoimun di Chicago, IL
12 kajian untuk Penyakit Autoimun sedang mencari peserta di lokasi dalam dan sekitar Chicago (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
A Phase IIa Study of ICG318 CAR-T in Refractory Systemic Lupus Erythematosus With or Without Lupus Nephritis
Mengambil pesertaFasa 2
- University of Chicago, Chicago
RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
Mengambil pesertaFasa 2/3
- Ann & Robert H. Lurie Children's Hospital of Chicago - Accepting Young Adult and Juvenile Patients, Chicago
- Northwestern Memorial Hospital - Accepting Adult Patients, Chicago
- The University of Chicago Medical Center - Accepting Adult and Juvenile Patients, Chicago
Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy
Mengambil pesertaFasa 2
- University of Chicago, Department of Medicine: Rheumatology, Chicago
A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
Mengambil pesertaFasa 1
- The University of Chicago Medical Center, Chicago
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
Mengambil pesertaFasa 1/2
- Northwestern Memorial Hospital, Chicago
- The University of Chicago Medical Center, Chicago
A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes Mellitus
Mengambil pesertaFasa 1/2
- University of Illinois Hospital & Health Sciences System, Chicago
RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
Mengambil pesertaFasa 2/3
- Northwestern Memorial Hospital, Chicago
- The University of Chicago Medical Center, Chicago
RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis
Mengambil pesertaFasa 1/2
- Northwestern Memorial Hospital, Chicago
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Mengambil pesertaKajian pemerhatian
- Northwestern Memorial Hospital, Chicago
- Rush University Medical Center, Chicago
- University of Illinois at Chicago, Chicago
- dan 2 lagi
Study of Single Doses of SBT777101 in Subjects With Rheumatoid Arthritis
Mengambil pesertaFasa 1
- Northwestern University, Chicago
A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
Mengambil pesertaFasa 1/2
- Northwestern University, Chicago
The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
- University of Chicago Medical Center, Chicago
Kajian Penyakit Autoimun di bandar lain
- Houston, TX21 kajian
- Washington, DC19 kajian
- New York City, NY19 kajian
- Philadelphia, PA16 kajian
- Durham, NC15 kajian
- Boston, MA13 kajian
- Los Angeles, CA12 kajian
- Dallas, TX9 kajian
- Cleveland, OH8 kajian
- Milwaukee, WI8 kajian
- Atlanta, GA8 kajian
- Portland, OR8 kajian
Kajian lain di Chicago
- Kanser Paru-paru Bukan Sel Kecil61 kajian
- Kanser Payudara58 kajian
- Kanser (semua jenis)51 kajian
- Kanser Metastatik45 kajian
- Kanser Prostat45 kajian
- Obesiti41 kajian
- Kanser Paru-paru41 kajian
- Kanser Ovari36 kajian
- Strok34 kajian
- Kanser Kolorektal33 kajian
- Kegagalan Jantung31 kajian
- Berat Badan Berlebihan28 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.